Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL SODIUM vs AXOTAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
Preoperative sedation,Daytime sedation,Insomnia (short-term treatment),Status epilepticus (adjunct),Withdrawal syndrome (off-label)
Tension headache
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP2C9, CYP2C19, and CYP3A4; conjugated with glucuronic acid; excreted renally.
Butalbital is metabolized primarily by CYP2C19; acetaminophen is metabolized mainly via glucuronidation by UGT1A1 and UGT1A6, sulfation by SULT1A1, and minor oxidation by CYP2E1.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%).
25-35%, primarily to albumin
98-99% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.5-0.8 L/kg; distributes widely into tissues, crosses blood-brain barrier
0.15-0.25 L/kg, indicating distribution mainly in extracellular fluid and limited tissue penetration.
Oral: 80-100% (rapid absorption); IM: complete
Oral: 85-95%; intramuscular: 90-100%; intravenous: 100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min). For e GFR 30-50 m L/min: reduce dose by 25% and monitor for CNS depression. e GFR >50 m L/min: no adjustment.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min). Use with caution in mild-moderate impairment due to acetaminophen and butalbital accumulation.
Contraindicated in Child-Pugh Class C. Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75% or use alternative. Avoid in severe hepatic impairment.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). In Child-Pugh A or B, reduce dose or extend interval; maximum acetaminophen 2000 mg/day, avoid butalbital if possible.
Not recommended for children <6 years. For children 6-12 years: sedative 5-15 mg orally 3-4 times daily; hypnotic not typically used. For adolescents >12 years: adult dosing with caution. Maximum single dose: 30 mg. Weight-based: 2-3 mg/kg/day divided every 6-8 hours, not to exceed 100 mg/day.
Not recommended for children under 12 years. For ages 12-18: same as adult dose (1-2 tablets) but limit to 4 tablets per day and monitor for sedation.
Start with lowest effective dose (e.g., 15 mg orally for sedation). Maximum dose: 50 mg per dose. Caution due to increased sensitivity, risk of falls, and cognitive impairment. Avoid hypnotic use. Consider non-barbiturate alternatives.
Start at lower dose (1 tablet every 6 hours) due to increased sensitivity to butalbital (c NS depression, falls) and acetaminophen hepatotoxicity risk; limit to 4 tablets per day, avoid in frail elderly.
Barbiturates are habit-forming. Tolerance, psychological and physical dependence may occur. Withdrawal symptoms include delirium, convulsions, and death. Abrupt cessation after prolonged use is not recommended.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is usually associated with doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
Respiratory depression risk; use caution in hepatic impairment, renal impairment, elderly, or debilitated patients; avoid abrupt discontinuation; may cause paradoxical excitement; monitor for hypersensitivity reactions.
Hepatotoxicity with acetaminophen overdose; risk of rhabdomyolysis, angioedema, Stevens-Johnson syndrome; butalbital dependence and withdrawal; CNS depression; impairment of mental or physical abilities; avoid concurrent alcohol use.
Hypersensitivity to barbiturates, porphyria, severe respiratory disease, severe hepatic impairment, history of addiction to sedative-hypnotics.
Hypersensitivity to barbiturates or acetaminophen; porphyria; severe hepatic impairment; respiratory depression; history of substance abuse.
Avoid grapefruit juice as it may alter metabolism. Limit or avoid alcohol; concurrent use increases CNS depression risk. Take with food if GI upset occurs; avoid high-fat meals as they may slow absorption.
Avoid alcohol intake; concurrent use increases risk of acetaminophen hepatotoxicity. Grapefruit juice may increase caffeine levels; limit consumption. High-fat meals may delay absorption of butalbital. Maintain adequate hydration; caffeine has mild diuretic effect.
First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third trimester: Neonatal withdrawal syndrome, respiratory depression, and hemorrhagic disease due to vitamin K deficiency. FDA Category D.
Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second and third trimesters: Increased risk of fetal/neonatal toxicity including cardiac arrhythmias, hypoglycemia, polyhydramnios, preterm birth, and neonatal goiter. Avoid if possible; weigh risks vs. benefits.
Excreted in breast milk; M/P ratio estimated 0.3-0.5. Risk of infant sedation, poor feeding, and withdrawal. Contraindicated in breastfeeding unless essential. Monitor for drowsiness, weight gain, and developmental milestones.
Lithium is excreted into human milk (M/P ratio 0.3-0.8). Breastfeeding is not recommended due to risk of neonatal toxicity (hypotonia, hypothermia, cyanosis, ECG changes). Monitor infant serum levels if breastfeeding is continued.
Increased clearance (up to 50% higher) in pregnancy, especially third trimester. Dose may need to be increased by 30-50% to maintain therapeutic effect. Monitor serum levels and adjust to minimum effective dose.
Dose adjustments are often necessary due to increased glomerular filtration rate and expanded plasma volume. Monitor serum levels closely (every 2-4 weeks in second and third trimesters). Dose may need to be increased or given in divided doses (e.g., 3 times daily) due to faster clearance. Postpartum: reduce dose promptly to pre-pregnancy levels within 24 hours after delivery to avoid toxicity from narrowed volume of distribution.
Barbiturate with rapid onset used for preoperative sedation and seizure control. Respiratory and CNS depression risk is dose-dependent; avoid in porphyria. Tolerance develops with prolonged use; withdrawal can be life-threatening. Use as second-line for status epilepticus after benzodiazepines. Highly protein-bound; monitor for interactions with warfarin and oral contraceptives.
AXOTAL (butalbital/acetaminophen/caffeine) is a combination analgesic for tension-type headaches. Butalbital is a barbiturate with addiction potential; limit use to less than 2 days per week to avoid medication overuse headache (MOH). Acetaminophen hepatic toxicity risk increases with chronic alcohol use or pre-existing liver disease. Caffeine may cause withdrawal headaches upon abrupt cessation.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants (e.g., opioids, benzodiazepines).,Do not drive or operate machinery until you know how this drug affects you.,Do not stop suddenly; abrupt discontinuation can cause withdrawal seizures.,Inform your doctor if you have a history of porphyria, liver disease, or depression.,Use effective contraception; this drug may reduce hormonal contraceptive efficacy.
Do not exceed 4 tablets per day to avoid acetaminophen overdose (max 4000 mg/day).,Avoid alcohol while taking this medication due to risk of liver damage.,This drug can be habit-forming; use only as prescribed for headache attacks, not for prophylaxis.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Discontinue and seek medical help if you experience signs of liver injury (jaundice, dark urine) or allergic reaction (rash, swelling).,Caffeine content may interfere with sleep or exacerbate anxiety; limit other caffeine sources.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL SODIUM vs AXOTAL, answered by our medical review team.
BUTABARBITAL SODIUM is a Barbiturate that works by Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.. AXOTAL is a Barbiturate Combination Analgesic that works by Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL SODIUM and AXOTAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL SODIUM is: Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.. The standard adult dose of AXOTAL is: Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARBITAL SODIUM and AXOTAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARBITAL SODIUM is classified as Category C. First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third tr. AXOTAL is classified as Category C. Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.